Eleven Biotherapeutics (EBIO) Shares Gap Up to $0.93

Eleven Biotherapeutics Inc (NASDAQ:EBIO) gapped up before the market opened on Wednesday . The stock had previously closed at $0.93, but opened at $0.93. Eleven Biotherapeutics shares last traded at $0.91, with a volume of 1102870 shares.

Eleven Biotherapeutics (NASDAQ:EBIO) last released its earnings results on Monday, November 20th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter.

Several hedge funds have recently made changes to their positions in EBIO. Municipal Employees Retirement System of Michigan acquired a new position in shares of Eleven Biotherapeutics during the 3rd quarter valued at about $382,000. Virtu KCG Holdings LLC acquired a new position in shares of Eleven Biotherapeutics during the 2nd quarter valued at about $175,000. Finally, Vanguard Group Inc. boosted its position in shares of Eleven Biotherapeutics by 17.4% during the 2nd quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 30,600 shares during the last quarter. 3.84% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally posted by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.com-unik.info/2018/01/26/eleven-biotherapeutics-ebio-shares-gap-up-to-0-93.html.

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit